Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: An update

Bangladesh Medical Research Council Bulletin

Volumn 31, Issue 3, 2005, Pages 88-94

  Giasuddin, A S M ^a   Hoque, M E ^b   Ahmed, Z U ^b  

^a UNIVERSITY OF DHAKA   (Bangladesh)

^b DHAKA MEDICAL COLLEGE   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; COLLAGEN TYPE 2; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248337414     PISSN: 03779238     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989; 299-302.
2. Clements MJ. Cytokines; Oxford: BIOS Scientific Publications Ltd; 1991.
3. Stites DP, Terr AI. Basic Human Immunology, 1st Edition; Connecticut: Appleton & Lange; 1991: 78-100.
4. Giasuddin ASM, Ziu MM. Views for future development of cytokines in health and disease: Implications for clinical medicine. J Islam Acad Sci 1996; 9: 67-74.
5. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-87.
6. Dalgleish AG. The immune response to HIV: potential for immunotherapy? Immunol Today 1995; 16: 356-58.
7. Feldmann M, Brennan FM, Maini RN. From the laboratory to the clinic: Evaluation of cytokines in rheumatoid arthritis highlights TNF-α as a new therapeutic target.The Immunologist 1994; 2: 172-76.
8. Chapel H, Haeney M, Misbah J, Snowden N. Essentials of Clinical Immnology, Fourth Edition; Oxford: Blackwell Science; 1999: 183-90.
9. Wordsworth BP. Rheumatoid arthritis. In: Weatherall DJ, Ledingham JGG, Warell DA (Editors). Oxford Textbook of Medicine, Vol. 3, Third Edition; Oxford: Oxford University Press; 1996: 2953-65.
10. Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al (Editors). Harrison's Principles of Internal Medicine, Vol. 2, 14th Edition; New York: McGraw-Hill; 1998: 1880-88.
11. Buchan G, Barrett K, Fujita T, et al. Detection of activated products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2),IL-2 receptor and IFN-γ. Clin Exp Immunol 1988; 71: 295-301.
12. Buchan G, Barrett K, Turner M, et al. Interleukin-I and tumour necrosis factor mRNA expression in rheumatoid arthititis: Prolonged production of IL-Iα. Clin Exp Immunol 1988; 73: 449-55.
13. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interlukin-I production in rheumatoid arthritis. Lancet 1989; ii: 244-47.
14. Chu CQ, Field M, Allard S, et al. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implication for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992; 31: 653-61.
15. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen- induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-88.
16. Keffer J, Probert LHC, Geogopoulos S, et al. Transgenetic mice expressing human tumour necrosis factor: A predective genetic model of arthritis. EMBO J 1991; 10:4025-31.
17. Elliott MJ, Maini RN, Feldmann M. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 1993; 36: 1681-90.
18. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1105-10.
19. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-63.
20. Charles P, Elliot MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-28.
21. Ellott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor alpha. Arthritis Rheum 1998 Mar; 41: 564-65.
22. Bathon JM, Martin RW, Fleischmann RM. A comparison of etanercept and methotrexate in patients with early rheumotaid arthritis. N Engl J Med 2000; 343: 1586-93.
23. Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotech 1999; 17: 666-69.
24. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat Med 2003; 9: 47-52.
25. Mathisen PM, Tuohy VK. Gene therapy in the treatment of autoimmune disease. Immunol Today 1998; 19: 103-5.
26. Martino G, Furlan R, Galbiati F, et al. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult Scler 1998; 4: 222-27.
27. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with inflixiMoAb anti-tumor necrosis factor antibodies in Crohn's disease: European multicenter trial. Gastroenterology 1999; 116:1029-34.
28. Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing remitting multiple sclerosis. CNS Drugs 2002; 16: 563-78.
29. Maini RN. Testing immunological concepts by clinical trials in rheumatoid arthritis. The Immunologist 1994; 2: 147-48.
30. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin Exp Immunol 2003; 132: 185-92.